About
Small Molecule Cancer Drugs
HepaRx is developing a small molecule cancer drug that inhibits heparanase (Hpa) enzymatic activity in order to stop the spread of cancer cells. The company is employing the Hpa crystal structure for drug design and development. Hpa has been evaluated extensively as a target for drug development, showing substantial involvement in disease progression and high-level expression in various cancer types including pancreatic, lung, breast, and mesothelioma. HepaRx has been operating in the framework of the biotech accelerator FutuRx.
Identity
| Name | HepaRx |
|---|---|
| Slug | heparx |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwOH20pAJDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Jul 2018 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | |
| HQ address | Ilan Ramon Street 2, Ness Ziona, Israel |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
oncologydrug-designpharma-companiesbiopharmaceutical
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}